LUCAS (Lucentis Compared to Avastin Study) (LUCAS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01127360
Recruitment Status : Completed
First Posted : May 20, 2010
Last Update Posted : January 16, 2015
Information provided by (Responsible Party):
Oslo University Hospital

May 19, 2010
May 20, 2010
January 16, 2015
March 2009
August 2014   (Final data collection date for primary outcome measure)
Mean change in VA at 1 and 2 years as measured with the ETDRS chart [ Time Frame: After 1 and 2 years ]
Mean change in VA at 1 and 2 years as measured with the ETDRS chart (with a non-inferiority limit of 5 letters)
Same as current
Complete list of historical versions of study NCT01127360 on Archive Site
  • Number of treatments. [ Time Frame: After 1 and 2 years ]
    Number of treatments.
  • Proportion of patients losing fewer than 15 letters on ETDRS chart [ Time Frame: After 1 and 2 years ]
    Proportion of patients losing fewer than 15 letters on ETDRS chart
  • Macular morphology as measured by FA and OCT after 2 years. [ Time Frame: After 2 years ]
    Macular morphology as measured by FA and OCT after 2 years.
  • Adverse events [ Time Frame: 2 years ]
    Frequency of ophthalmological and other health related adverse events during the 2 year study.
  • Number of non-responders. [ Time Frame: After 2 years ]
    Number of non-responders.
Same as current
Not Provided
Not Provided
LUCAS (Lucentis Compared to Avastin Study)
LUCAS. A Randomized, Prospective, Multicenter Study Comparing the Effect of Intravitreal Injection of Bevacizumab to Ranibizumab When Given to Patients With Neovascular Age-related Macular Degeneration

Age-related macular degeneration (AMD) is the most common cause of blindness in individuals over 50 years of age. Bevacizumab and ranibizumab are two agents developed by the American pharmaceutical corporation Genentech, both of which inhibit blood vessel growth factors. These drugs, when injected intraocularly, reduce the pathological growth of blood vessels in the macular area of the eye. Bevacizumab (Avastin) is an antibody developed for intravenous treatment of metastasized colon cancer. Ranibizumab (Lucentis) is an antibody fragment developed from a similar antibody. It was introduced 2006 as an effective treatment for wet AMD. Treatment costs are, however, up to 50 times higher compared to use of bevacizumab. Avastin has shown similar effects to ranibizumab, and has been used off-label in many countries, both before and after Lucentis received approval. There is thus a recognized need for large randomized studies to garner proper scientific proof of Avastin's effectiveness regarding exudative AMD.

LUCAS is a randomized multicenter study, performed in Norway, comparing ranibizumab and bevacizumab use for AMD. The goal of the study was to demonstrate if the two agents were equivalent regarding both efficacy and safety. A total of 441 patients with objective evidence of wet AMD were randomized to a double-blind treatment with ranibizumab or bevacizumab over the course of 2 years. The treatment interval was determined by a "Treat and Extend" protocol.

LUCAS (LUcentis Compared to Avastin Study) A randomized, double-blind, prospective multicenter study comparing the effect of intravitreal injection of bevacizumab (Avastin) to ranibizumab (Lucentis) when given to patients with exudative (wet) age-related macular degeneration in Norway.

Version: 4, Protocol: 166-09, EudraCT: 2008-004225-41


LUCAS is a prospective, randomized, multicenter study comparing the effects of intravitreal injection of bevacizumab (Avastin) with ranibizumab (Lucentis) when given to patients with exudative (wet) AMD in Norway.

The study will include 420 patients to be recruited starting March 2009. The study will continue for 2 years after completed enrollment.


LUCAS is a multicenter, randomized, double-blind study, with 1:1 parallel groups treated with either bevacizumab (Avastin) 0.05 ml (25 mg/ml) or ranibizumab (Lucentis) 0,05 ml (10 mg/ml). The drug is injected intravitreally according to an "inject and extend" principle (5).

Randomization will be stratified by center and performed with minimization according to prognostic factors.

Treatment Regimen:

Bevacizumab (Avastin) will be given as an intravitreal injection of 0.05ml (25 mg/ml) from a vial containing 4 ml.

Ranibizumab (Lucentis) will be given as an intravitreal injection of 0.05 ml (10 mg/ml) from a vial containing 0.23 ml.

Follow-up and treatment will follow a principle called "inject and extend." This connotes the following: initial follow-up and injection with a 4 week intervals until the macula is dry. When dry, then follow-up and injection will be increased 2 weeks at a time. If the patient has a recurrence of wet AMD, then the interval is reduced by 2 weeks at a time until the macula is once again dry. The shortest interval is 4 weeks. When once again extending, the treatment interval shall not be as long as the interval of the original recurrence, as this could confer risk for new activity. Therefore further follow-up and injection occurs at the "ideal" interval which is hereby defined as being 2 weeks less than that of the original recurrence. With this method, the patient receives an injection at each follow-up, presuming that no complications occur. The maximum interval is limited to 12 weeks. Treatment will continue for 2 years. After the study is completed, then the patient is to be offered continued treatment, in accordance with the ophthalmology department's routines, If there is no response to treatment after 3 injections with a 4 week interval, then the patient shall be removed from the study and be offered alternative treatment, such as combination treatment with photodynamic therapy (PDT).

Phase 4
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Exudative Age-related Macular Degeneration
  • Drug: Bevacizumab
    Intravitreal injections
    Other Name: Avastin
  • Drug: Ranibizumab
    Intravitreal injections
    Other Name: Lucentis
  • Experimental: Bevacizumab
    Bevacizumab 1,25 mg, intravitreal injections every 4th to 12th week
    • Drug: Bevacizumab
    • Drug: Ranibizumab
  • Active Comparator: Ranibizumab
    Ranibizumab 0,5 mg, intravitreal injection, every 4th to 12th week
    • Drug: Bevacizumab
    • Drug: Ranibizumab
Not Provided

*   Includes publications given by the data provider as well as publications identified by Identifier (NCT Number) in Medline.
Same as current
August 2014
August 2014   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  1. Men and women.
  2. Age ≥50 years.
  3. Wet AMD in the study eye, defined as:

    Not previously treated active choroidal neovascular membrane (CNV), including retinal angiomatous proliferation (RAP), with edema involving the fovea as demonstrated with optical coherence tomography (OCT) and fluorescein angiography (FA). FA shall not be older than 7 days at randomization.

    Best corrected visual acuity (BCVA) in the study eye 20/25 - 20/320.

  4. Only one eye of each study patient may be recruited into the study. If the non-study eye is being treated with intravitreal anti-VEGF therapy, or develops wet AMD, then the same drug being used in the study eye shall be used in the non-study eye. Treatment must be given double-blind in the non-study eye as well.

Exclusion Criteria:

  1. Previous treatment of CNV in the study eye.
  2. Participation in another AMD study, or use of other investigational medicines.
  3. Anti-VEGF treatment in the non-study eye during the last 4 weeks.
  4. Earlier or current treatment with systemic anti-VEGF drug.
  5. Subretinal hemorrhage and/or fibrosis that involves ≥50 percent of the CNV lesion in the study eye.
  6. CNV of other pathogenesis, such as pathologic myopia (defined as having a spherical equivalent of >8 diopters myopia) or Presumed Ocular Histoplasmosis Syndrome (POHS).
  7. Presence of retinal diseases other than AMD (diabetic retinopathy, macular hole, etc) that lead to loss of visual acuity in the study eye.
  8. Cataract that will presumably require operation within 2 years or other intraocular surgery or laser treatment during the last 3 months.
  9. Impaired visualization of the retina (by vitreous hemorrhage, corneal dystrophy, etc.) that may hamper adequate diagnosis.
  10. Intraocular pressure ≥25 mm Hg, measured before mydriasis, or uncontrolled glaucoma as evaluated by the examining ophthalmologist.
  11. Active uveitis in the study eye or intraocular inflammation after use of Lucentis or Avastin in the non-study eye.
  12. Infection in one or both eyes.
  13. Premenopausal women who do not use appropriate birth control, or who are nursing.
  14. Patients who for mental or physical reasons are unable to comply with the study's procedures,
  15. Serious disease where there is a probability of death within the duration of the study.
Sexes Eligible for Study: All
50 Years and older   (Adult, Older Adult)
Contact information is only displayed when the study is recruiting subjects
Not Provided
Not Provided
Oslo University Hospital
Oslo University Hospital
Not Provided
Study Director: Andreas Moan Director of Research at Oslo University Hospital
Study Chair: Ragnheidur Bragadottir, MD. PhD. Department of Ophthtalmology, Oslo University Hospital
Principal Investigator: Karina Berg, MD. Department of Ophthalmology, Oslo University Hospital
Study Chair: Terje Pedersen, Professor Department of Preventative Medicine, Oslo University Hospital
Oslo University Hospital
January 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP